HALO
Halozyme Therapeutics, Inc. NASDAQ$64.57
After hrs
$71.34
+8.30%
Mkt Cap $7.6B
52w Low $47.50
49.2% of range
52w High $82.22
50d MA $66.14
200d MA $68.47
P/E (TTM)
24.2x
EV/EBITDA
8.8x
P/B
157.0x
Debt/Equity
0.0x
ROE
649.2%
P/FCF
12.5x
RSI (14)
—
ATR (14)
—
Beta
1.03
50d MA
$66.14
200d MA
$68.47
Avg Volume
1.8M
About
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other t…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | 2.15 | -0.24 | -111.2% | 80.48 | -3.5% | -9.0% | -10.5% | -11.8% | -12.2% | -12.6% | — |
| Nov 3, 2025 | AMC | 1.63 | 1.72 | +5.5% | 66.20 | +2.2% | +2.8% | +3.2% | +3.3% | +3.1% | +2.7% | — |
| Aug 5, 2025 | AMC | 1.23 | 1.54 | +25.2% | 60.81 | +3.7% | +2.5% | +2.1% | +3.4% | +3.4% | +5.3% | — |
| May 6, 2025 | AMC | 0.95 | 1.11 | +16.8% | 59.38 | +7.3% | +18.1% | +14.1% | +10.9% | +12.1% | -15.4% | — |
| Feb 18, 2025 | AMC | 1.17 | 1.26 | +7.7% | 57.90 | +1.9% | -0.2% | -0.8% | -0.3% | +1.0% | +0.2% | — |
| Oct 31, 2024 | AMC | 0.98 | 1.27 | +29.6% | 50.57 | +10.1% | +13.0% | +15.6% | +16.1% | +19.9% | +18.0% | — |
| Aug 6, 2024 | AMC | 0.76 | 0.91 | +19.7% | 51.94 | +7.8% | +4.2% | +4.9% | +6.3% | +8.0% | +7.8% | — |
| May 7, 2024 | AMC | 0.70 | 0.79 | +12.9% | 41.21 | +1.8% | +1.9% | +6.4% | +4.7% | +5.8% | +6.3% | — |
| Feb 20, 2024 | AMC | 0.83 | 0.82 | -1.2% | 36.00 | +4.8% | +6.6% | +10.3% | +12.7% | +10.2% | +10.7% | — |
| Nov 6, 2023 | AMC | 0.71 | 0.75 | +5.6% | 35.26 | +4.0% | +10.0% | +4.2% | +4.0% | +5.6% | +6.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19 | Benchmark | Maintains | Buy → Buy | — | $73.23 | $73.94 | +1.0% | -1.6% | -3.1% | -3.5% | -3.9% | -3.9% |
| Feb 19 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $73.23 | $73.94 | +1.0% | -1.6% | -3.1% | -3.5% | -3.9% | -3.9% |
| Jan 8 | TD Cowen | Maintains | Buy → Buy | — | $75.11 | $75.18 | +0.1% | -4.0% | -3.5% | -3.6% | -4.6% | -2.9% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.11 | $65.28 | +0.3% | +3.4% | +4.7% | +5.0% | +5.1% | +5.8% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $72.66 | $72.54 | -0.2% | -1.7% | -6.3% | -8.4% | -11.0% | -13.4% |
| Nov 18 | Goldman Sachs | Maintains | Neutral → Neutral | — | $70.56 | $70.08 | -0.7% | -0.7% | -0.4% | -2.3% | -0.3% | +4.9% |
| Nov 4 | Citizens | Maintains | Market Outperform → Market Outperform | — | $66.20 | $67.64 | +2.2% | +2.8% | +3.2% | +3.3% | +3.1% | +2.7% |
| Oct 27 | JP Morgan | Maintains | Neutral → Neutral | — | $66.15 | $66.80 | +1.0% | -0.5% | -1.1% | -1.3% | -2.3% | -1.5% |
| Oct 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $67.03 | $67.07 | +0.1% | -0.8% | -0.2% | -1.9% | -0.2% | -1.3% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $66.65 | $67.42 | +1.2% | -0.4% | +0.3% | +0.6% | -0.3% | +0.3% |
Recent Filings
8-K · 5.03
! Medium
Halozyme Therapeutics, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Halozyme Therapeutics shifted its fiscal year-end, which may affect timing of future earnings reports and investor comparisons with prior periods.
Apr 24
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Leadership transitions create uncertainty around strategic direction and operational continuity, potentially triggering stock volatility until investors assess the successor's qualifications and vision.
Apr 13
8-K
Unknown — 8-K Filing
Directors gain broad indemnification coverage for legal expenses and settlements, which may reduce accountability for questionable decisions and increase shareholder litigation risk and governance concerns.
Mar 26
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of an executive at Halo Collective (HALO) could signal leadership instability or strategic shifts, potentially impacting operational execution and investor confidence depending on the executive's role and replacement quality.
Mar 12
8-K
Halozyme Therapeutics, Inc. -- 8-K Filing
Halozyme's royalty revenue surged 52% to $868 million in 2025, with acquisitions of hyperconcentration technologies supporting robust 2026 guidance projecting 22-30% total revenue growth and 87-99% earnings-per-share expansion.
Feb 17
Data updated apr 25, 2026 12:55pm
· Source: massive.com